Is the greater the response to the targeted drug Erdafitinib, the better the effect?

Erdafitinib (Erdafitinib) is a targeted drug, and its efficacy is not necessarily directly proportional to the patient's response to the drug. The effect of drug therapy is affected by many factors, including individual differences among patients, tumor characteristics, drug metabolism, and drug distribution in the body.

First, individual differences play a key role in how patients respond to medications. Each patient's physiological characteristics, genetic makeup, and metabolic capabilities vary, which may result in different responses to the same drug. Some patients may be more sensitive to erdafitinib, while others may show a smaller response.

Secondly, tumor characteristics also affect drug efficacy. The targeting effect of a drug depends on the presence and activity of the target in the tumor. If the target expression level is higher in tumor cells, it may be more susceptible to the effects of the drug, resulting in a more significant therapeutic effect.

Drug metabolism and distribution are also factors that influence efficacy. The patient's ability to metabolize drugs and the distribution of the drug in the body may affect the concentration of the drug, thereby affecting the efficacy of the drug. Therefore, it is crucial to ensure that patients use their medications correctly and as recommended by their doctor to maintain stable drug concentrations.

Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.